Shield Therapeutics Investor Relations Material
Latest events
Trading Update
Shield Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Shield Therapeutics plc
Access all reports
Shield Therapeutics plc is a specialty pharmaceutical company focused on the development and commercialization of treatments for iron deficiency and related conditions. The company's lead product, Accrufer/Feraccru® (ferric maltol), is an oral iron therapy designed to treat iron deficiency in patients who cannot tolerate traditional iron supplements. Shield Therapeutics operates in Europe and the United States, partnering with healthcare providers and pharmaceutical distributors to expand its market reach. The company is headquartered in Gateshead, United Kingdom, and its shares are listed on the AIM.
)
)
)